Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)
Protalix BioTherapeutics' (PLX) quarterly Notes Payables came in at $4.1 million in Q4 2020, down 5.0% year-on-year from $4.3 million in Q1 2020, and down 4.98% quarter-over-quarter from $4.3 million in Q3 2020.
Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020) Analysis & Trends
Protalix BioTherapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $4.1 million for Q4 2020.
- On a quarterly basis, Notes Payables fell 5.0% year-over-year to $4.1 million in Q4 2020; TTM through Dec 2020 was $4.1 million, a 5.0% decrease from a year earlier, with the FY2020 full-year figure at $4.1 million, down 5.0% from the prior year.
- Notes Payables declined to $4.1 million in Q4 2020 per PLX's latest filing, from $4.3 million in the prior quarter.
- Across five years, Notes Payables topped out at $4.3 million in Q4 2019 and bottomed at $4.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4.09 Mn |
| Sep 30, 2020 | 4.30 Mn |
| Jun 30, 2020 | 4.30 Mn |
| Mar 31, 2020 | 4.30 Mn |
| Dec 31, 2019 | 4.30 Mn |